In California Institute of Technology v. Broadcom Limited (“Cal Tech”), the Federal Circuit clarified the scope of inter partes review (IPR) estoppel under 35 U.S.C. § 315(e)(2), finding that it precludes petitioners from asserting in district court any grounds raised or that could have been raised in their IPR petitions. The Federal Circuit’s decision, however, did not resolve all open questions regarding IPR estoppel.
One issue, in particular, percolating in the district courts is whether estoppel applies to prior art that technically couldn’t have been raised in an IPR, but is related to art that could have been. For example, if a petitioner raised or could have raised a publication describing a product, can the same petitioner challenge validity in district court using the product itself? On this issue, the district courts are split, reaching different conclusions.
Under 35 U.S.C. § 315(e), IPR estoppel applies to “any ground that the petitioner raised or reasonably could have raised during that inter partes review.” In Cal Tech, the Federal Circuit explained that “estoppel applies not just to claims and grounds asserted in the petition and instituted for consideration by the Board, but to all grounds not stated in the petition but which reasonably could have been asserted against the claims included.”
Under 35 U.S.C. § 311(b), a “petitioner in an inter partes review may request to cancel as unpatentable 1 or more claims of a patent only on a ground that could be raised under section 102 or 103 and only on the basis of prior art consisting of patents or printed publications.” Invalidity grounds under 35 U.S.C. § 101 for subject-matter eligibility, therefore, cannot be raised in an IPR. Likewise, petitioners cannot challenge validity in an IPR under 35 U.S.C. § 112 based on indefiniteness or the written description or enablement requirements.
As noted above, IPRs are limited to “patents or printed publications.” Petitioners, therefore, cannot file IPRs alleging anticipation or obviousness grounds based (fully or partially) on, for example, systems “in public use, on sale, or otherwise available to the public.” See 35 U.S.C. § 102. The anticipation and obviousness grounds in a petition for IPR must be limited to printed publications, including but not limited to patents, patent publications, journal articles, product manuals, and other similar printed documents.
In a number of district court actions, patent owners have argued that defendants who previously filed IPRs are estopped from raising grounds of invalidity even though they include non-printed prior art. These assertions are often founded in fairness, arguing that a defendant shouldn’t be able to use a product as a prior art reference when a publication on the exact same product existed and could have been used (or actually was) in the IPR.
Some district courts have accepted these arguments. For example, in one case, the District of Delaware explained that the Patent Act “distinguishes between grounds and evidence.” See Wasica Finance GmbH v. Schrader Int'l, Inc., 432 F. Supp. 3d 448, 454 (D. Del. 2020). According to the court, the estoppel of § 315(e)(2) “applies to grounds” and “a petitioner is estopped from proceeding in litigation on those grounds, even if the evidence used to support those grounds was not available to be used in the IPR.” Id. (emphasis in original). Thus, the court found invalidity arguments estopped when they were based on products that were “materially identical” to publications that could have been used in the IPR. Id.
Some courts, however, have rejected this view as contrary to the plain text of the statute. In Medline Industries Inc. v. CR Bard Inc., 2020 WL 5512132, at *4 (N.D. Ill. Sept. 14, 2020), the district court essentially rejected the Wasica court’s distinction between “evidence” and “grounds,” finding “ground” referred to “specific pieces of prior art” used in the IPR challenge. Based on that interpretation, the court held that if “Congress had wanted to estop an IPR petitioner from pursuing invalidity grounds that relied upon a physical product in a particular situation, such as where a patent or printed publication disclosed the same claim limitations as the product, it could have provided language to that effect.” But according to the district court, “Congress did not do so, and this failure indicates Congress did not intend for the IPR estoppel provision to be that broad.” Id.
The Medline court, however, did caveat its ruling, finding that a defendant must actually rely on the product. It can’t simply use publications and then say those publications represent a product. Id. This is consistent with a number of district courts that have held one cannot disguise an estopped publication as a system. See, e.g., SPEX Technologies Inc. v. Kingston Technology Corp., 2020 WL 4342254, at *15 (C.D. Cal. June 16, 2020) (holding a prior art system invalidity theory was not precluded “absent a showing that the system invalidity theory is a patent or printed publication theory in disguise”).
This split in the district courts as to the correct interpretation of 35 U.S.C. § 315(e) is certain to be resolved at some point by the Federal Circuit. Until then, patent challengers may wish to err on the side of caution, and assume when preparing their IPRs that they won’t be able to later raise prior art system invalidity theories in district court where publications describe the very same systems.
For additional articles on the topic of IPR, please see:
Tony Blum represents clients before the PTAB in post-grant proceedings and litigates intellectual property suits throughout the country.
Although we would like to hear from you, we cannot represent you until we know that doing so will not create a conflict of interest. Also, we cannot treat unsolicited information as confidential. Accordingly, please do not send us any information about any matter that may involve you until you receive a written statement from us that we represent you (an â€˜engagement letterâ€™).
By clicking the â€˜ACCEPTâ€™ button, you agree that we may review any information you transmit to us. You recognize that our review of your information, even if you submitted it in a good faith effort to retain us, and, further, even if you consider it confidential, does not preclude us from representing another client directly adverse to you, even in a matter where that information could and will be used against you. Please click the â€˜ACCEPTâ€™ button if you understand and accept the foregoing statement and wish to proceed.